XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (6828)	7/29/1998 3:00:00 AM
From: Tharos	Read Replies (1) of 17367

George, I am not prone to paying as close attention to the scientific specifics as you are, consequently I tend to deal in generalities with the science issues. One thing I have been noticing in biotech firms -- new R&D is specifically aiming itself at selecting genes, molecules, proteins, etc. that can be customized. This approach is readily apparent in the cancer therapy arena. Having the rights to a molecule like BPI with so many promising "customizations" is the dream of may biotech firms, or so one would think, given the number of firms scrambling to create customized therapy processes to an attack specific body parts, or specific diseases, or specific cancers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next